Valeant Pharmaceuticals International will acquire the assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc. (a J&J business) for $345 million. The acquisition, which follows Valeant’s purchase of Sanofi’s Dermik unit earlier this week, includes prescription brands RETIN-A MICRO, ERTACZO, and RENOVA.  Total revenue for the product portfolio was approximately $150 million in 2010.  The transaction is subject to certain closing conditions and regulatory approv...